WASHINGTON — In the photo, the two men are grinning widely: the CEO of WuXi Biologics and the incoming CEO of the biotechnology industry’s largest trade group.
The photo, posted to WuXi’s LinkedIn page, shows the pair in a firm, congratulatory glad hand over John Crowley’s appointment to lead the Biotechnology Innovation Organization.
Three months later, in March, sister company WuXi AppTec and BIO had ended their relationship, and Crowley was openly professing his support for legislation that would all but ban many U.S. biotechs from doing business with the Chinese behemoth.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect